Revista nº 812

Terapia génica suicida contra el cáncer | Piñeiro Silva C. Actual Med. 2021; 106(812): 54- 65 64 in suicidal gene therapy. BMC Cancer. 2017;17(1):129. DOI:  10.1186/s12885-017-3123-x 26. Yang WS, Park SO, Yoon AR, et al. Suicide cancer gene therapy using pore-forming toxin, streptolysin O. Molecular cancer therapeutics. 2006;5(6):1610-9. DOI:  10.1158/1535-7163.MCT-05-0515 27. Rama AR, Prados J, Melguizo C, et al. E phage gene trans- fection associated to chemotherapeutic agents increases apoptosis in lung and colon cancer cells. Bioeng Bugs. 2011;2(3):163-7. DOI:  10.4161/bbug.2.3.15533 28. Bae Y, Song SJ, Mun JY, Ko KS, Han J, Choi JS. Apop- tin Gene Delivery by the Functionalized Polyamidoam- ine (PAMAM) Dendrimer Modified with Ornithine Induc- es Cell Death of HepG2 Cells. Polymers. 2017;9(6):197. DOI:  10.3390/polym9060197 29. Peng W, Chen J, Huang YH, Sawicki JA. Tightly-regulated suicide gene expression kills PSA-expressing prostate tu- mor cells. Gene Ther. 2005;12(21):1573-80. DOI:  10.1038/ sj.gt.3302580 30. Pappenheimer AM, Jr. Diphtheria toxin. Annu Rev Biochem. 1977;46:69-94. DOI:  10.1146/annurev. bi.46.070177.000441 31. Fogar P, Navaglia F, Basso D, et al. Heat-induced trans- cription of diphtheria toxin A or its variants, CRM176 and CRM197: implications for pancreatic cancer gene thera- py. Cancer Gene Ther. 2010;17(1):58-68. DOI:  10.1038/ cgt.2009.48 32. He M, Wang Y, Chen X, et al. Spatiotemporally controlla- ble diphtheria toxin expression using a light-switchable transgene system combining multifunctional nanopar- ticle delivery system for targeted melanoma therapy. J Control Release. 2020;319:1-14. DOI:  10.1016/j.jcon- rel.2019.12.015 33. Morlon-Guyot J, Méré J, Bonhoure A, Beaumelle B. Pro- cessing of Pseudomonas aeruginosa exotoxin A is dis- pensable for cell intoxication. Infection and immunity. 2009;77(7):3090-9. DOI:  10.1128/IAI.01390-08 34. Cao GW, Qi ZT, Pan X, et al. Gene therapy for human co- lorectal carcinoma using human CEA promoter contro led bacterial ADP-ribosylating toxin genes human CEA: PEA & DTA gene transfer. World J Gastroenterol. 1998;4(5):388- 91. DOI:  10.3748/wjg.v4.i5.388 35. Zhao J, Jin J, Zhang X, et al. Transfection of Smac sensi- tizes tumor cells to etoposide-induced apoptosis and era- dicates established human hepatoma in vivo. Cancer Gene Ther. 2006;13(4):420-7. DOI:  10.1038/sj.cgt.7700910 36. Bai D, Xia X, Yow CMN, Chu ESM, Xu C. Hypocrellin B-en- capsulated nanoparticle-mediated rev-caspase-3 gene transfection and photodynamic therapy on tumor cells. Eur J Pharmacol. 2011;650(2):496-500. DOI:  10.1016/j. ejphar.2010.10.017 37. Huang J, Gao J, Lv X, et al. Target gene therapy of glio- ma: overexpression of BAX gene under the control of both tissue-specific promoter and hypoxia-inducible element. Acta Biochim Biophys Sin. 2010;42(4):274-80. DOI:  10.1093/abbs/gmq016 38. Li J, Pan J, Zhu X, et al. Recombinant adenovi- rus-p53 (Gendicine) sensitizes a pancreatic carcino- ma cell line to radiation. Chinese journal of cancer re- search. 2013;25(6):715-21. DOI:  10.3978/j.issn.1000- 9604.2013.11.12 39. Chen GX, Zhang S, He XH, Liu SY, Ma C, Zou XP. Clinical utility of recombinant adenoviral human p53 gene therapy: current perspectives. OncoTargets Ther. 2014;7:1901-9. DOI:  10.2147/OTT.S50483 40. Zhang W-W, Li L, Li D, et al. The First Approved Gene Therapy Product for Cancer Ad-p53 (Gendicine): 12 Years in the Clinic. Hum Gene Ther. 2018;29(2):160-79. DOI:  10.1089/hum.2017.218 41. Shi SW, Li B, Dong Y, et al. In Vitro and Clinical Stu- dies of Gene Therapy with Recombinant Human Ade- novirus-p53 Injection for Malignant Melanoma. Hum Gene Ther Clin Dev. 2019;30(1):7-18. DOI:  10.1089/ humc.2018.112 42. Deng B, Sun T, Tang B, et al. Surgery combi- ned with adenoviral p53 gene therapy for treatment of non-small cell lung cancer: a phase II study. Oncotarget. 2017;8(63):107089-95. DOI:  10.18632/oncotarget.22333 43. Tamura RE, Lana MG, Costanzi-Strauss E, Strauss BE. Combination of cabazitaxel and p53 gene therapy abo- lishes prostate carcinoma tumor growth. Gene Ther. 2020;27(1):15-26. DOI:  10.1038/s41434-019-0071-x 44. Xu X, Liu A, Bai Y, et al. Co-delivery of resveratrol and p53 gene via peptide cationic liposomal nanocarrier for the synergistic treatment of cervical cancer and breast can- cer cells. J Drug Deliv Sci Technol. 2019;51:746-53. DOI: 10.1016/j.jddst.2018.05.008 45. Griffith TS, Broghammer EL. Suppression of Tumor Growth Following Intralesional Therapy with TRAIL Recombinant Adenovirus. Mol Ther. 2001;4(3):257-66. DOI:  10.1006/ mthe.2001.0439 46. Kim CY, Jeong M, Mushiake H, et al. Cancer gene ther- apy using a novel secretable trimeric TRAIL. Gene Ther. 2006;13(4):330-8. DOI:  10.1038/sj.gt.3302658 47. Lin T, Zhang L, Davis J, et al. Combination of TRAIL gene therapy and chemotherapy enhances antitumor and an- timetastasis effects in chemosensitive and chemore- sistant breast cancers. Mol Ther. 2003;8(3):441-8. DOI:  10.1016/s1525-0016(03)00203-x 48. Morales DR, Morris AD. Metformin in Cancer Treat- ment and Prevention. Annu Rev Med. 2015;66(1):17-29. DOI:  10.1146/annurev-med-062613-093128